Tribenzor is a drug owned by Cosette Pharmaceuticals Inc. It is protected by 2 US drug patents filed in 2013 out of which all have expired. Based on its patents and exclusivities, its generic launch date is estimated to be Oct 25, 2016. Details of Tribenzor's patents and their expiration are given in the table below.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| These drug patents focus on the other aspects of the drug like dosage, mode of administration (oral, tablet, capsules, liquids etc). | |||
|
US5616599 (Pediatric) | Angiotensin II antagosist 1-biphenylmethylimidazole compounds and their therapeutic use |
Oct, 2016
(9 years ago) |
Expired
|
| US5616599 | Angiotensin II antagosist 1-biphenylmethylimidazole compounds and their therapeutic use |
Apr, 2016
(9 years ago) |
Expired
|
FDA has granted several exclusivities to Tribenzor. Till the time
these exclusivities
are active, no other company can market a generic or bioequivalent version of Tribenzor, regardless of the status of it's patents. These exclusivities hence play a crucial role in
delaying the generic
launch. Given below are details of the exclusivities granted to
Tribenzor.
Exclusivity Information
Tribenzor holds 1 exclusivities. All of its exclusivities have expired in 2013. Details of Tribenzor's exclusivity codes and their expiration dates are given below.
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Combination(NC) | Jul 23, 2013 |
US patents provide insights into the exclusivity only within the United States, but
Tribenzor is protected by patents in multiple countries.
Understanding
the full scope
of patent protection is crucial in strategizing market entry. By looking at the broader patent
landscape, you can
identify markets with weaker patent protection which could be ideal generic entry points. The
following section offers
details on Tribenzor's family patents as well as insights into
ongoing legal events
on those patents.
Tribenzor's Family Patents
Explore Our Curated Drug Screens
Generic Launch
Generic Release Date:
Tribenzor's generic launch date based on the last expiry date of its patents and exclusivities combined is estimated to be Oct 25, 2016 (This date is subject to change depending upon the patent filing activities by the drug owner or exclusivity additions to its drug application)
Tribenzor Generic API suppliers:
Amlodipine Besylate; Hydrochlorothiazide; Olmesartan Medoxomil is the generic name for the brand Tribenzor. 6 different companies have already filed for the generic of Tribenzor, with Hetero Labs Ltd V having the maximum number of approved applications. Check out the entire list of companies who have already received approval for Tribenzor's generic
Alternative Brands for Tribenzor
Tribenzor which is used for lowering high blood pressure., has several other brand drugs in the same treatment category . Given below is the list of those companies and their brand drugs, to help you identify new opportunities, assess competitors, and plan your market strategies more effectively.
| Drug Owner | Drug Name | Treatment Area | ||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Abbott |
| |||||||||||||||
| Abbvie |
| |||||||||||||||
| Adhera |
| |||||||||||||||
| Allergan |
| |||||||||||||||
| Ani Pharms |
| |||||||||||||||
| Azurity |
| |||||||||||||||
| Boehringer Ingelheim |
| |||||||||||||||
| Cosette |
| |||||||||||||||
| Noden Pharma |
| |||||||||||||||
| Novartis |
| |||||||||||||||
| Upjohn |
| |||||||||||||||
| Waylis Therap |
| |||||||||||||||
About Tribenzor
Tribenzor is a drug owned by Cosette Pharmaceuticals Inc. It is used for lowering high blood pressure. Tribenzor uses Amlodipine Besylate; Hydrochlorothiazide; Olmesartan Medoxomil as an active ingredient. Tribenzor was launched by Cosette in 2010.
Approval Date:
Tribenzor was approved by FDA for market use on 23 July, 2010.
Active Ingredient:
Tribenzor uses Amlodipine Besylate; Hydrochlorothiazide; Olmesartan Medoxomil as the active ingredient. Check out other Drugs and Companies using Amlodipine Besylate; Hydrochlorothiazide; Olmesartan Medoxomil ingredient
Treatment:
Tribenzor is used for lowering high blood pressure.
Dosage:
Tribenzor is available in tablet form for oral use. Given below is detailed information on Dosage -
| Strength | Dosage Form | Availability | Application Pathway |
|---|---|---|---|
| EQ 10MG BASE;25MG;40MG | TABLET | Prescription | ORAL |
| EQ 5MG BASE;12.5MG;20MG | TABLET | Prescription | ORAL |
| EQ 5MG BASE;12.5MG;40MG | TABLET | Prescription | ORAL |
| EQ 5MG BASE;25MG;40MG | TABLET | Prescription | ORAL |
| EQ 10MG BASE;12.5MG;40MG | TABLET | Prescription | ORAL |